Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 11521 Athens, Greece.
J Immunol. 2014 May 1;192(9):4122-33. doi: 10.4049/jimmunol.1300633. Epub 2014 Mar 28.
Experimental autoimmune encephalomyelitis (EAE) is a valuable model for studying immunopathology in multiple sclerosis (MS) and for exploring the interface between autoimmune responses and CNS tissue that ultimately leads to lesion development. In this study, we measured gene expression in mouse spinal cord during myelin oligodendrocyte gp35-55 peptide-induced EAE, using quantitative RT-PCR, to identify gene markers that monitor individual hallmark pathological processes. We defined a small panel of genes whose longitudinal expression patterns provided insight into the timing, interrelationships, and mechanisms of individual disease processes and the efficacy of therapeutics for the treatment of MS. Earliest transcriptional changes were upregulation of Il17a and sharp downregulation of neuronal and oligodendrocyte marker genes preceding clinical disease onset, whereas neuroinflammatory markers progressively increased as symptoms and tissue lesions developed. EAE-induced gene-expression changes were not altered in mice deficient in IKKβ in cells of the myeloid lineage compared with controls, but the administration of a selective inhibitor of soluble TNF to mice from the day of immunization delayed changes in the expression of innate inflammation, myelin, and neuron markers from the presymptomatic phase. Proof of principle that the gene panel shows drug screening potential was obtained using a well-established MS therapeutic, glatiramer acetate. Prophylactic treatment of mice with glatiramer acetate normalized gene marker expression, and this correlated with the level of therapeutic success. These results show that neurons and oligodendrocytes are highly sensitive to CNS-directed autoimmunity before the development of clinical symptoms and immunopathology and reveal a role for soluble TNF in mediating the earliest changes in gene expression.
实验性自身免疫性脑脊髓炎(EAE)是研究多发性硬化症(MS)免疫病理学以及探索自身免疫反应与中枢神经系统组织之间界面的有价值模型,这些界面最终导致病变发展。在这项研究中,我们使用定量 RT-PCR 测量了髓鞘少突胶质细胞糖蛋白 35-55 肽诱导的 EAE 期间小鼠脊髓中的基因表达,以鉴定监测个体标志性病理过程的基因标志物。我们定义了一小部分基因,其纵向表达模式提供了对个体疾病过程的时间、相互关系和机制以及治疗多发性硬化症的疗法的疗效的深入了解。最早的转录变化是在临床疾病发作前上调 Il17a 和急剧下调神经元和少突胶质细胞标志物基因,而神经炎症标志物则随着症状和组织病变的发展而逐渐增加。与对照组相比,在髓样细胞中缺乏 IKKβ 的小鼠中,EAE 诱导的基因表达变化没有改变,但从免疫接种之日起对小鼠给予可溶性 TNF 的选择性抑制剂可延迟先天炎症、髓鞘和神经元标志物表达的变化从无症状期开始。使用一种成熟的 MS 治疗药物,醋酸格拉替雷,获得了该基因谱显示药物筛选潜力的原理证明。用醋酸格拉替雷对小鼠进行预防性治疗可使基因标志物表达正常化,这与治疗成功水平相关。这些结果表明,在出现临床症状和免疫病理学之前,神经元和少突胶质细胞对中枢神经系统定向自身免疫非常敏感,并揭示了可溶性 TNF 在介导基因表达的最早变化中的作用。